Sign in

CIK 0001628171

  • Large accelerated filer

Revolution Medicines, Inc.

Sign in to watch
Ticker
RVMD
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
472029180
Phone
+1 650-481-6801
Business address
700 SAGINAW DR, REDWOOD CITY, CA, 94063

Securities

  • RVMD Common Stock Nasdaq
  • RVMDW Warrant Nasdaq
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$85,328,124
in 21 filings, $85.3M under 10b5-1 plans

Net −$85,328,124. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-10-31 Patel Sushil Director Option exercise · Stock Option (Right to Buy) 10b5-1 −5,000 13,400
2024-10-14 Kelsey Stephen Michael See Remarks Option exercise 10b5-1 +16,666 $4.09 $68K 281,074
2024-10-14 Kelsey Stephen Michael See Remarks Sale 10b5-1 −14,056 $49.38 $694K 267,018
2024-10-14 Kelsey Stephen Michael See Remarks Sale 10b5-1 −2,610 $50.08 $131K 264,408
2024-10-14 Kelsey Stephen Michael See Remarks Option exercise · Stock Option (Right to Buy) 10b5-1 −16,666 23,332
2024-10-11 Horn Margaret A Chief Operating Officer Option exercise 10b5-1 +44,631 $4.09 $183K 176,951
2024-10-11 Horn Margaret A Chief Operating Officer Option exercise 10b5-1 +5,369 $4.09 $22K 182,320
2024-10-11 Horn Margaret A Chief Operating Officer Sale 10b5-1 −50,000 $50.34 $2.5M 132,320
2024-10-11 Horn Margaret A Chief Operating Officer Option exercise · Stock Option (Right to Buy) 10b5-1 −44,631 0
2024-10-11 Horn Margaret A Chief Operating Officer Option exercise · Stock Option (Right to Buy) 10b5-1 −5,369 97,382
2024-10-11 GOLDSMITH MARK A See Remarks Option exercise 10b5-1 +30,000 $4.09 $123K 330,170
2024-10-11 GOLDSMITH MARK A See Remarks Sale 10b5-1 −30,000 $50.36 $1.5M 300,170
2024-10-11 GOLDSMITH MARK A See Remarks Option exercise · Stock Option (Right to Buy) 10b5-1 −30,000 241,229
2024-10-11 Anders Jack Chief Financial Officer Option exercise 10b5-1 +10,000 $2.68 $27K 108,932
2024-10-11 Anders Jack Chief Financial Officer Sale 10b5-1 −10,000 $50.30 $503K 98,932
2024-10-11 Anders Jack Chief Financial Officer Option exercise · Stock Option (Right to Buy) 10b5-1 −10,000 2,814
2024-10-11 Cislini Jeff General Counsel Option exercise 10b5-1 +6,000 $36.57 $219K 51,634
2024-10-11 Cislini Jeff General Counsel Sale 10b5-1 −6,000 $50.17 $301K 45,634
2024-10-11 Cislini Jeff General Counsel Option exercise · Stock Option (Right to Buy) 10b5-1 −6,000 36,000
2024-10-08 Weber Barbara Director Sale 10b5-1 −5,200 $48.02 $250K 13,065

Page 21 of 29 · 569 trades